TY - JOUR
T1 - Tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors in neonates recovering from necrotizing enterocolitis
AU - Lima-Rogel, Victoria
AU - Calhoun, Darlene A.
AU - Maheshwari, Akhil
AU - Torres-Montes, Abraham
AU - Roque-Sanchez, Raul
AU - Garcia, Maria G.
AU - Christensen, Robert D.
N1 - Funding Information:
Supported in part by grants HD-42326 (DAC), HD-01180 (DAC), and HL-61798 (RDC) from the National Institutes of Health.
PY - 2003/4
Y1 - 2003/4
N2 - Objective: To assess the tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors enternally administered in neonates who were NPO because of necrotizing enterocolitis (NEC). Study Design: A phase I trial was accomplished among 30 neonates. Patients received 5, 10, or 20 mL enterally of the study solution/kg/day divided into every 3-hour dosing, for 3 days prior to when feedings of milk were to resume. The occurrence of emesis, gastric residuals, diarrhea, bloody stools, abdominal distention, skin rashes and death were sought. Results: Gestational ages ranged from 25.2 to 41.1 weeks. A total of 16 neonates had Stage IA NEC, six Stage IB, and eight Stage IIA. The solutions was well tolerated in all 30; none developed diarrhea, guaiac positive or bloody stools, or abdominal distention. Administration of the solution was not prematurely discontinued in any infant. Two neonates died secondary to late-onset sepsis remote from the study period. Conclusions: Enteral administration of a sterile isotonic electrolyte solution containing select recombinant growth factors was well tolerated by neonate with NEC.
AB - Objective: To assess the tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors enternally administered in neonates who were NPO because of necrotizing enterocolitis (NEC). Study Design: A phase I trial was accomplished among 30 neonates. Patients received 5, 10, or 20 mL enterally of the study solution/kg/day divided into every 3-hour dosing, for 3 days prior to when feedings of milk were to resume. The occurrence of emesis, gastric residuals, diarrhea, bloody stools, abdominal distention, skin rashes and death were sought. Results: Gestational ages ranged from 25.2 to 41.1 weeks. A total of 16 neonates had Stage IA NEC, six Stage IB, and eight Stage IIA. The solutions was well tolerated in all 30; none developed diarrhea, guaiac positive or bloody stools, or abdominal distention. Administration of the solution was not prematurely discontinued in any infant. Two neonates died secondary to late-onset sepsis remote from the study period. Conclusions: Enteral administration of a sterile isotonic electrolyte solution containing select recombinant growth factors was well tolerated by neonate with NEC.
UR - http://www.scopus.com/inward/record.url?scp=0038486029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038486029&partnerID=8YFLogxK
U2 - 10.1038/sj.jp.7210894
DO - 10.1038/sj.jp.7210894
M3 - Article
C2 - 12732856
AN - SCOPUS:0038486029
SN - 0743-8346
VL - 23
SP - 200
EP - 204
JO - Journal of Perinatology
JF - Journal of Perinatology
IS - 3
ER -